Escalation of Therapy in Seropositive Rheumatoid Arthritis with High Disease Activity

Prognostic Factors Requiring Aggressive Therapy

First‑Line Biologic Choice

Alternative Biologic Options (when TNF inhibitors are unsuitable)

Optimizing Methotrexate Before Biologic Addition

Treatment Timeline, Targets, and Monitoring

Glucocorticoid Bridge Therapy

Conventional DMARD Triple Therapy (when Biologics Are Unavailable)

Common Pitfalls to Avoid

Timing and Criteria for Initiating Biologic DMARDs in Rheumatoid Arthritis

Indications for Starting a Biologic

Poor‑Prognostic Features that Accelerate Biologic Use

Alternative Conventional DMARD Strategies (When Biologics Are Unavailable)

Preferred Biologic Choices and Combination Strategies

Treatment Targets and Monitoring

Special Population Considerations